Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: A meta-analysis

Digestive Diseases and Sciences

Volumn 59, Issue 2, 2014, Pages 436-445

  Song, Jian ^a   Su, Hong ^a   Zhou, Yang Yang ^a   Guo, Liang Liang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2 (COX 2); Disease free survival (DFS); Gastric cancer; Meta analysis; Overall survival (OS)

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STOMACH CANCER;

CHI-SQUARE DISTRIBUTION; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MULTIVARIATE ANALYSIS; RISK FACTORS; STOMACH NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84896706620     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2917-1     Document Type: Article

References (71)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893-2917.
2. Herszenyi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci. 2010;14:249-258.
3. Xing X, Tang YB, Yuan G, et al. The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer. 2013;132:2589-2596.
4. Zhang QW, Liu L, Chen R, et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:2903-2908.
5. Peng L, Zhan P, Zhou Y, et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39:9473-9484.
6. Thiel A, Mrena J, Ristimäki A. Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev. 2011;30:387-395.
7. Wu WK, Sung JJ, Lee CW, et al. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010;295:7-16.
8. Fujimura T, Ohta T, Oyama K, et al. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol. 2006;12:1336-1345.
9. Oshima H, Oshima M, Inaba K, et al. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004;23:1669-1678.
10. Thiel A, Narko K, Heinonen M, et al. Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer. 2012;131:1032-1041.
11. Jiang H, Wang J, Zhao W. Cox-2 in non-small cell lung cancer: a meta-analysis. Clin Chim Acta. 2013;419:26-32.
12. Lee JY, Myung SK, Song YS. Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecol Oncol. 2013;129:613-619.
13. Huang M, Chen Q, Xiao J, et al. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer. 2013;132:363-373.
14. Almeida PR, Ferreira FV, Santos CC, et al. Immunoexpression of cyclooxygenase-2 in primary gastric carcinomas and lymph node metastases. World J Gastroenterol. 2012;18:778-784.
15. Joo YE, Rew JS, Seo YH, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003;37:28-33.
16. Tang H, Wang J, Bai F, et al. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest. 2008;26:60-67.
17. Zhang X, Wu Q, Gan L, et al. Reduced group IVA phospholipase A2 expression is associated with unfavorable outcome for patients with gastric cancer. Med Oncol. 2013;30:454.
18. Jiang H, Qiao XL, Huang FY. Expressions and clinical significance of Smad4 and Cox-2 in gastric cancer. J Clin Med Pract. 2012;16:30-33.
19. Fanelli MF, Chinen LT, Begnami MD, et al. The influence of transforming growth factor-a, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 2012;61:153-161.
20. Gou HF, Chen XC, Zhu J, et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res. 2011;30:14.
21. Zhang C, Wang XQ, Xu C, et al. Expression of cyr-61 and cox-2 in gastric carcinoma and its clinical significance. J China Med Univ. 2011;40:744-748.
22. Sun GY, Luo DH, Wu JS, et al. The expression of NICD and COX-2 in gastric carcinoma tissues and its clinical biological significance. J Med Res. 2011;40:61-66.
23. Tatsuwaki H, Tanigawa T, Watanabe T, et al. Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci. 2010;101:550-558.
24. Mrena J, Wiksten JP, Kokkola A, et al. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol. 2010;31:1-7.
25. Li Y, Tan BB, Fan LQ, et al. Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis. Hepatogastroenterology. 2010;57:1435-1441.
26. Zhai JH, Li N, Zhang L, et al. Expression of P16, C-MYC and COX-2 in gastric carcinoma and relationship with the prognosis of patients. J Zhejiang Coll Tradit Chin Med. 2009;33:321-322.
27. Yamac D, Ayyildiz T, Coskun U, et al. Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma. Pathol Res Pract. 2008;204:527-536.
28. Ye SC, Wang JY, Yuan GZ, et al. Expression of COX-2 and P-gp and its prognosis in gastric carcinoma. Chin Gen Pract. 2008;11:291-294.
29. Lazar D, Taban S, Ardeleanu C, et al. Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival. Rom J Morphol Embryol. 2008;49:371-379.
30. Kolev Y, Uetake H, Takagi Y, et al. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol. 2008;15:2336-2344.
31. Da MX, Wu XT, Wang J, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 2008;39:92-99.
32. Gudis K, Tatsuguchi A, Wada K, et al. Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum Pathol. 2007;38:1826-1835.
33. Li M, Liu W, Zhu YF, et al. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer. Acta Oncol. 2006;45:1115-1119.
34. Joo YE, Chung IJ, Park YK, et al. Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci. 2006;21:871-876.
35. Linder N, Haglund C, Lundin M, et al. Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol. 2006;59:965-971.
36. Yu JR, Wu YJ, Qin Q, et al. Expression of cyclooxygenase-2 in gastric cancer and its relation to liver metastasis and long-term prognosis. World J Gastroenterol. 2005;11:4908-4911.
37. Okano H, Shinohara H, Miyamoto A, et al. Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome. Clin Cancer Res. 2004;10:6938-6945.
38. Shi H, Xu JM, Hu NZ, et al. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol. 2003;9:1421-1426.
39. Joo YE, Oh WT, Rew JS, et al. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion. 2002;66:222-229.
40. Leung WK, To KF, Ng YP, et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001;84:335-339.
41. Lee TL, Leung WK, Lau JY, et al. Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer. Cancer Lett. 2001;168:133-140.
42. Chen CN, Sung CT, Lin MT, et al. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg. 2001;233:183-188.
43. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519-525.
44. Nordmann AJ, Kasenda B, Briel M. Meta-analyses: what they can and cannot do. Swiss Med Wkly. 2012;142:w13518.
45. McShane LM, Altman DG, Sauerbrei W. Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol. 2006;28:99-105.
46. Chen M, Cai E, Huang J, et al. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:1126-1134.
47. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7:8-16.
48. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
49. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
50. Zhao HC, Qin R, Chen XX, et al. Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol. 2006;12:7598-7603.
51. Han SL, Tang HJ, Hua YW, et al. Expression of COX-2 in stomach cancers and its relation to their biological features. Dig Surg. 2003;20:107-114.
52. Al-Moundhri MS, Al-Hadabi I, Al-Mawaly K, et al. Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer. Med Oncol. 2012;29:1739-1747.
53. Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg. 2006;243:64-73.
54. Vidal O, Soriano-Izquierdo A, Pera M, et al. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg. 2008;12:1005-1014.
55. Mrena J, Wiksten JP, Thiel A, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11:7362-7368.
56. Mrena J, Wiksten JP, Nordling S, et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol. 2006;59:618-623.
57. Kolev Y, Uetake H, Iida S, et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol. 2007;14:2738-2747.
58. Jamieson NB, Carter CR, McKay CJ, et al. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011;17:3316-3331.
59. Li L, Zhao J, Wu Z, et al. Meta-analysis: clinicopathological and prognostic significance of cyclooxygenase-2 expression on oesophageal squamous cell carcinoma. Aliment Pharmacol Ther. 2009;30:589-596.
60. Peng L, Zhou Y, Wang Y, et al. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS ONE. 2013;8:e58891.
61. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273:114-127.
62. Tatsuguchi A, Matsui K, Shinji Y, et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol. 2004;35:488-495.
63. Sun WH, Sun YL, Fang RN, et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol. 2005;35:707-713.
64. Lukaszewicz-Zaja̧c M, Mroczko B, Szmitkowski M. Gastric cancer - the role of matrix metalloproteinases in tumor progression. Clin Chim Acta. 2011;412:1725-1730.
65. Gamba CA, Swetter SM, Stefanick ML, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the women's health initiative. Cancer. 2013;119:1562-1569.
66. Gammon MD, Terry MB, Arber N, et al. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004;13:34-39.
67. Yang P, Zhou Y, Chen B, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci. 2010;55:1533-1539.
68. Yu J, Tang BD, Leung WK, et al. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention. World J Gastroenterol. 2005;11:41-45.
69. Liu H, Huang P, Xu X, et al. Anticancer effect of celecoxibvia COX-2 dependent and independent mechanisms in human gastric cancers cells. Dig Dis Sci. 2009;54:1418-1424.
70. Keller JJ, Giardiello FM. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther. 2003;2:140-149.
71. Russo A, Bazan V, Migliavacca M, et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res. 2000;6:178-184.